• Home
  •  / CytomX Therapeutics

CytomX Therapeutics

OverviewSuggest Edit

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
TypePublic
Founded2008
HQSouth San Francisco, CA, USMap
Websitecytomx.com
Employee Ratings3.4More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)158(+16%)
Revenue (FY, 2019)$57.5 M(-3%)
Share Price (Jan 2021)$7.9 (+2%)
Cybersecurity ratingAMore

Key People/Management at CytomX Therapeutics

Sean A. McCarthy

Sean A. McCarthy

President, Chief Executive Officer and Chairman
Amy C. Peterson

Amy C. Peterson

EVP, Chief Development Officer
Carlos Campoy

Carlos Campoy

SVP, Chief Financial Officer
Alison Joly

Alison Joly

SVP, Program and Alliance Management
W. Michael Kavanaugh

W. Michael Kavanaugh

SVP, Chief Scientific Officer, Head of Research and Non-Clinical Development
Charles S. Fuchs

Charles S. Fuchs

Director
Show more

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
151 Oyster Point Blvd #400
Show all (1)

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Revenue

CytomX Therapeutics's revenue was reported to be $57.49 m in FY, 2019
USD

Revenue (Q3, 2020)

17.8m

Net income (Q3, 2020)

(14.7m)

EBIT (Q3, 2020)

(14.9m)

Market capitalization (15-Jan-2021)

366.6m

Closing stock price (15-Jan-2021)

7.9

Cash (30-Sept-2020)

176.8m

EV

215.4m
CytomX Therapeutics's current market capitalization is $366.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.7m15.0m71.6m59.5m57.5m

Revenue growth, %

95%

General and administrative expense

12.6m19.9m25.6m33.5m36.8m

R&D expense

28.4m54.8m92.3m103.9m131.6m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.9m2.2m3.1m3.5m11.7m8.8m24.1m14.2m21.3m12.5m29.5m9.0m10.7m49.6m16.6m17.8m

General and administrative expense

4.1m5.0m4.6m5.0m5.7m6.0m6.2m7.4m9.0m8.1m9.7m9.4m8.5m9.6m8.7m8.6m

R&D expense

9.2m13.4m12.7m13.3m14.6m28.1m28.9m22.5m25.6m27.5m36.4m30.8m28.0m42.8m24.1m24.0m

Operating expense total

13.2m18.4m17.4m18.4m20.3m34.1m35.2m29.8m34.6m35.7m46.1m40.2m36.4m52.4m32.7m32.7m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

59.8m104.6m177.5m247.6m188.4m

Accounts Receivable

744.0k2.2m10.1m97.0k13.0k

Prepaid Expenses

4.4m9.3m7.2m

Inventories

2.3m3.9m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

36.2m67.9m62.4m59.8m85.7m272.9m284.2m142.2m132.9m259.8m190.4m149.4m164.6m143.3m291.4m176.8m

Accounts Receivable

406.0k316.0k285.0k240.0k213.0k158.0k40.2m81.0k25.1m56.0k44.0k10.0m7.0k130.0m206.0k543.0k

Prepaid Expenses

878.0k3.4m3.4m4.4m4.1m4.6m4.8m5.5m6.4m7.9m8.4m7.5m9.1m9.1m6.9m5.6m

Current Assets

115.1m184.5m199.6m183.3m166.9m340.7m376.4m367.0m366.7m472.5m405.1m366.7m334.8m400.1m366.6m340.3m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.4m)(58.9m)(43.1m)(84.6m)(102.2m)

Depreciation and Amortization

1.2m1.7m1.6m1.9m146.0k

Accounts Payable

2.9m1.8m(2.4m)261.0k(374.0k)

Cash From Operating Activities

(27.4m)(2.0m)170.4m(75.5m)(140.5m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(23.9m)(16.0m)(30.2m)(44.9m)(8.3m)(33.5m)(43.7m)(15.5m)(28.9m)(52.4m)(14.1m)(43.1m)(66.8m)12.2m(3.5m)(18.2m)

Depreciation and Amortization

877.0k355.0k800.0k1.2m395.0k764.0k1.2m412.0k875.0k1.4m653.0k1.3m109.0k36.0k72.0k109.0k

Accounts Payable

749.0k246.0k(3.2m)(4.1m)(2.8m)79.0k(3.5m)1.1m(429.0k)2.8m5.2m3.0k152.0k52.0k579.0k(270.0k)

Cash From Operating Activities

(19.2m)(5.5m)10.2m(4.0m)(19.1m)154.1m148.4m(14.6m)(41.2m)(46.8m)(39.0m)(87.7m)(111.0m)(49.7m)47.4m22.7m
show all
USDQ3, 2015

Financial Leverage

-1.2 x
Show all financial metrics

CytomX Therapeutics Operating Metrics

FY, 2016

Patents (Foreign)

4

Patents (US)

13

Patents Pending

144

Phase I Trials Products

1
Show all operating metrics

CytomX Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

CytomX Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

CytomX Therapeutics Online and Social Media Presence

CytomX Therapeutics's Trends

Embed Graph

CytomX Therapeutics News and Updates

January 07, 2021

CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sea…
December 22, 2020

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appo…
December 03, 2020

CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced two post…
November 05, 2020

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT
October 06, 2020

CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research
June 26, 2020

Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - June 26, 2020 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. ("CytomX" or the "Company")(NASDAQ:CTMX) of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities clas…
Show more

CytomX Therapeutics Blogs

December 10, 2020

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of the Probody® Therapeutic (Pb-Tx) Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2-Negative Breast Cancer (mHR+/HER2− BC) and of CX-2009 as Monotherapy and in Combination Therapy With Pacmilimab (CX-072) in Metastatic Triple-Negative Breast Cancer (TNBC)

Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.
December 10, 2020

Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.
November 11, 2020

CytomX Therapeutics to Present at Upcoming Investor Conferences

CytomX Therapeutics to Present at Upcoming Investor Conferences Content Import Wed, 11/11/2020 - 16:02 CytomX Therapeutics to Present at Upcoming Investor Conferences November 11, 2020 at 4:01 PM EST This release is a backfill from a News Wire G…
November 05, 2020

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate Content Import Thu, 11/05/2020 - 08:03 CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Dr…
October 29, 2020

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT- SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody
October 27, 2020

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.
Show more

 CytomX Therapeutics Frequently Asked Questions

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Who are CytomX Therapeutics key executives?

    CytomX Therapeutics's key executives are Sean A. McCarthy, Amy C. Peterson and Carlos Campoy.

  • How many employees does CytomX Therapeutics have?

    CytomX Therapeutics has 158 employees.

  • What is CytomX Therapeutics revenue?

    Latest CytomX Therapeutics annual revenue is $57.5 m.

  • What is CytomX Therapeutics revenue per employee?

    Latest CytomX Therapeutics revenue per employee is $363.9 k.

  • Who are CytomX Therapeutics competitors?

    Competitors of CytomX Therapeutics include SQZ Biotech, Ablynx and Ajinomoto Althea.

  • Where is CytomX Therapeutics headquarters?

    CytomX Therapeutics headquarters is located at 151 Oyster Point Blvd #400, South San Francisco.

  • Where are CytomX Therapeutics offices?

    CytomX Therapeutics has an office in South San Francisco.

  • How many offices does CytomX Therapeutics have?

    CytomX Therapeutics has 1 office.